Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

R Mirza, Mansoor; J Monk, Bradley; Herrstedt, Jørn; M Oza, Amit; Mahner, Sven; Redondo, Andrés; Fabbro, Michel; A Ledermann, Jonathan; Lorusso, Domenica; Vergote, Ignace; E Ben-Baruch, Noa; Marth, Christian; Mądry, Radosław; D Christensen, René; S Berek, Jonathan; Dørum, Anne; V Tinker, Anna; du Bois, Andreas; González-Martín, Antonio; Follana, Philippe; Benigno, Benedict; Rosenberg, Per; Gilbert, Lucy; J Rimel, Bobbie; Buscema, Joseph; P Balser, John; Agarwal, Shefali; A Matulonis, Ursula; Investigators, ENGOT-OV16/NOVA

doi:10.1056/nejmoa1611310

Public

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

Published in The New England journal of medicine • Dec 1, 2016

NobleIDark:/48914/w1/20260526/23C57E7ERecord on NobleID

Authors:

Mansoor R Mirza

,

Bradley J Monk

,

Jørn Herrstedt

Abstract

BACKGROUND: Niraparib is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We sought to evaluate the efficacy of niraparib versus placebo as maintenance treatment for patients with platinum-sensitive, re...

Discussions